PTC Therapeutics Inc. / Censa Pharmaceuticals

Phenylketonuria (PKU) and BH4 Pathway Metabolic Diseases

17K US cases/yr · $600M Global PKU therapy market 2020 (Kuvan + Palynziq + medical foods) · ~$268M Total deal value (up to, incl. milestones)

Disease Overview

The PTC-Censa acquisition centers on phenylketonuria (PKU), an autosomal recessive inborn error of metabolism caused by phenylalanine hydroxylase (PAH) deficiency that prevents conversion of phenylalanine (Phe) to tyrosine. Untreated, accumulated Phe causes irreversible intellectual disability, seizures, and behavioral disorders. PKU affects approximately 1 in 15,000 newborns in the U.S. (~16,500 prevalent patients) under universal newborn screening, with broader BH4 pathway disorders adding several thousand additional patients across primary BH4 deficiency, GTP cyclohydrolase deficiency, and segawa syndrome. Standard of care is lifelong Phe-restricted medical food diet (formula plus Phe-free protein), supplemented in BH4-responsive subset (~30%) by Kuvan (sapropterin dihydrochloride, BioMarin) which functions as a synthetic BH4 cofactor. Palynziq (pegvaliase, BioMarin), an enzyme substitution PEGylated phenylalanine ammonia lyase, addresses the BH4-non-responsive adult majority but requires daily injection and carries a black box warning for anaphylaxis. CNSA-001 (sepiapterin) is a synthetic precursor that enters the BH4 biosynthesis pathway upstream of sapropterin, theoretically delivering broader patient response and lower Phe levels. WAC pricing for branded PKU therapy: Kuvan ~$100K/year; Palynziq ~$200K-300K/year.

Competitive Landscape

The PKU competitive landscape is small but commercially mature and undergoing generational change. BioMarin is the franchise anchor with two assets: Kuvan/sapropterin (synthetic BH4 cofactor, oral, BH4-responsive subset, generic entry late 2020) and Palynziq/pegvaliase (PEGylated phenylalanine ammonia lyase enzyme replacement, subcutaneous injection, broad applicability but black box anaphylaxis warning). Sepiapterin (CNSA-001 / PTC923) competes directly with Kuvan as a more potent BH4 precursor and was Phase 3-ready at acquisition with the APHENITY pivotal trial planned. Gene therapy approaches in development include BMN 307 (BioMarin AAV5-PAH, Phase 1/2 hold lifted 2022), HMI-102 (Homology Medicines AAVHSC15-PAH), and SYNB1618 (Synlogic engineered E. coli to consume Phe in gut, Phase 2). Adjacent BH4 pathway disorders (segawa syndrome, GTP cyclohydrolase deficiency) are addressed off-label with sapropterin and would be additional indication expansion targets for sepiapterin.